GAMMA Investing’s Gyre Therapeutics GYRE Stock Holding History

GAMMA Investing’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$962	Buy	146 +64	+78%	+$436	﹤0.01%	3889
2026 Q1	$572	Buy	+82	New	+$637	﹤0.01%	3926
2025 Q3	–	Sell	-124	Closed	-$911	–	3883
2025 Q2	$911	Sell	124 -112	-47%	-$977	﹤0.01%	3549
2025 Q1	$1.82K	Buy	236 +224	+1,867%	+$2.46K	﹤0.01%	3433
2024 Q4	$145	Buy	+12	New	+$154	﹤0.01%	3742

Other funds holding GYRE

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

GAMMA Investing's GYRE Position: Q2 2026 in Review

GAMMA Investing increased its Gyre Therapeutics (GYRE) stake by 78% in Q2 2026, buying an estimated $436 and bringing the position to 146 shares worth $962. The position accounts for ﹤0.01% of the portfolio, ranked #3889.

GAMMA Investing first reported a position in GYRE in Q4 2024 and has held it in 5 quarters since. The position peaked at $1.82K in Q1 2025. 3 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

GAMMA Investing held 146 shares of Gyre Therapeutics worth $962 as of Q2 2026.
GAMMA Investing bought 64 Gyre Therapeutics shares in Q2 2026, an estimated $436.
Gyre Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3889 holding.
GAMMA Investing first reported a position in Gyre Therapeutics in Q4 2024 and has held it in 5 quarters since.
GAMMA Investing's Gyre Therapeutics position peaked at $1.82K in Q1 2025.
3 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.